KOR

e-Article

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
Document Type
Journal
Source
BREAST CANCER RESEARCH AND TREATMENT; JAN 2006, 95 1, p45-p53, 9p.
Subject
Language
English
ISSN
01676806